The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Selinexor vs. SOC in penta-exposed MM: STORM & MAMMOTH analysis
Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, discusses the analysis of selinexor plus dexamethasone (Sd) vs. conventional care for triple class refractory, penta-exposed multiple myeloma in terms of overall survival (OS). This compared data from the STORM trial (NCT02336815) with real world data from the retrospective MAMMOTH study. While not an replacement for a prospective, randomized trial, this analysis suggested improved OS with Sd vs. conventional care in this group. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
